Mood Disorders Market Size to Reach USD 4.7 Billion by 2035, Impelled by Advancements in Treatment Options

Mood Disorders Market Outlook 2025-2035:

The 7 major mood disorders market reached a value of USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4.7 Billion by 2035, exhibiting a growth rate (CAGR) of 2.02% during 2025-2035. The Mood Disorders market is driven by the adding acceptance of non-invasive and minimally invasive treatments, similar as cognitive behavioral therapy (CBT), mindfulness- based curatives, electroconvulsive therapy (ECT), and transcranial magnetic stimulation (TMS). These approaches offer significant benefits by perfecting emotional regulation, reducing symptoms of depression and anxiety, and enhancing overall internal well- being without the need for long- term drug use. Psychotherapies similar as talk therapy are also gaining traction, as they offer sustainable results while minimizing side effects frequently associated with pharmacological treatments. The convenience and efficacity of these curatives, along with their capability to address various angles of mood diseases like depression, bipolar disorder, and generalized anxiety complaint, make them appealing to cases seeking more individualized and accessible treatment options. The growing acceptance of digital internal health tools, similar as virtual remedy platforms and self- help apps, also contributes to the expansion of the demand, making internal health care more affordable and accessible for people worldwide.

Advances in Early Detection and Diagnostic Technologies: Driving the Mood Disorders Market 

Ultramodern diagnostic and treatment technologies are transubstantiating the Mood Disorders market, enhancing the administration and aftereffects for patients. Advanced individual ways, similar as brain imaging (e.g., MRI and PET reviews) and functional MRI ( fMRI), enable the direct visualization and monitoring of brain exertion and changes associated with mood disorders. These advancements help in understanding the neurobiological mechanisms underpinning conditions like depression, bipolar complaint, and anxiety, allowing for precise assessment and substantiated treatment planning. also, inheritable testing and biomarker analysis are arising as tools for relating inheritable tendencies and underpinning pathophysiologies, easing personalized treatment strategies. The integration of artificial intelligence (AI) into diagnostics further enhances accurateness by enabling the category of mood diseases, severity assessment, and tracking treatment progress. AI- driven algorithms can help prognosticate patient responses to curatives, reducing the need for private evaluations. Non-invasive treatments, comparable as transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT), have gained favor for their effectiveness in treating severe mood diseases with minimal side effects and downtime. In addition, digital internal health tools similar as mobile apps and teletherapy platforms have revolutionized care delivery by offering real- time monitoring of patient symptoms, providing remedy and support remotely. These technologies have made internal health care more accessible, particularly for individuals in underserved or remote areas, guaranteeing timely interventions and reducing the threat of worsening conditions. Telemedicine platforms also broaden access to mental health services by facilitating remote consultations, diagnoses, and treatment plans, further enhancing patient care and improving outcomes. These innovations are helping to address the rising global demand for more accessible, personalized, and effective treatments for mood disorders.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The Mood Disorders market is expanding with the preface of new curatives combined with advanced pharmacological treatments. New medicines, both topical and oral, are being developed to target specific pathways involved in mood regulation and neurotransmitter imbalances. These curatives are aimed at perfecting the management of conditions similar as depression, bipolar complaint, and generalized anxiety complaint. The new specifics are characterized by enhanced efficacity, reduced side effects, and further targeted mechanisms, leading to bettered patient aftereffects and satisfaction. exploration in biological medicines is enhancing, particularly for the treatment of moderate to severe cases of mood disorders. This includes monoclonal antibodies that target pro-inflammatory cytokines like interleukin- 6 and tumor necrosis factor- alpha( TNF- α), which play roles not only in inflammation but also in the brain’s neurochemical processes that contribute to mood disorders. Advances in medicine delivery systems, similar as liposomal formulations, nanotechnology- grounded carriers, and hydrogels, enable more effective medicine delivery, concentrating the remedial agent directly in the target area while minimizing systemic side effects. Additionally, adjunctive treatments under investigation include probiotics and immunomodulators, which aim to restore balance to the gut-brain axis, further enhancing the body's natural defenses and supporting mental health. Combination therapies that integrate antidepressants with anti-inflammatory agents or psychotherapies show promise in treating the complex, multifaceted pathophysiology of mood disorders. Non-invasive pharmaceutical solutions, such as biofeedback and cognitive behavioral therapy (CBT), are gaining popularity for their ease of application and patient-centered approach. These advances are transforming the treatment landscape for mood disorders, making therapies more accessible, effective, and personalized for patients.

Marketed Therapies in Mood Disorders Market

Lamictal (Lamotrigine): GlaxoSmithKline

Lamictal (Lamotrigine) is an FDA-approved mood stabilizer commonly used for the treatment of bipolar disorder, particularly in preventing depressive episodes. It works by stabilizing electrical activity in the brain and regulating mood by inhibiting excessive glutamate release, offering a favorable side effect profile compared to other mood stabilizers.

Seroquel XR (Quetiapine): AstraZeneca

Seroquel XR (Quetiapine) is an extended-release atypical antipsychotic used to treat mood disorders, including major depressive disorder (MDD) and bipolar disorder. It helps stabilize mood by modulating neurotransmitters such as dopamine and serotonin, offering therapeutic benefits for both manic and depressive episodes.

Depakote (Valproate semisodium): AbbVie

Depakote (Valproate Semisodium) is a widely prescribed mood stabilizer used for the treatment of bipolar disorder, particularly in managing manic episodes. It helps regulate mood by enhancing GABA neurotransmission and stabilizing neuronal activity, making it effective for both acute mood episodes and maintenance therapy.

Emerging Therapies in Mood Disorders Market

SEP363856: Sunovion Pharmaceuticals

SEP363856, developed by Sunovion Pharmaceuticals, is a novel antipsychotic with a unique mechanism of action targeting TAAR1 (Trace Amine-Associated Receptor 1) and 5-HT1A receptors. It has shown promise in clinical trials for treating schizophrenia and mood disorders, offering significant symptom improvement with a lower risk of metabolic and extrapyramidal side effects compared to traditional antipsychotics.

TAK 653: Takeda

TAK-653 is a selective positive allosteric modulator of the AMPA receptor being developed by Takeda Pharmaceuticals for the treatment of mood disorders, particularly major depressive disorder (MDD). By enhancing glutamatergic signaling, it offers a novel mechanism of action with the potential for faster onset of antidepressant effects compared to traditional therapies.

Detailed list of emerging therapies in Mood Disorders is provided in the final report.

Leading Companies in the Mood Disorders Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global Mood Disorders market, several leading companies are at the forefront of developing integrated platforms to enhance the management of Mood Disorders. Some of the major players include GlaxoSmithKline, AstraZeneca, AbbVie, BioXcel Therapeutics, and others. These companies are driving innovation in the Mood Disorders market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for Mood Disorders.

​In January 2025, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray. This approval establishes SPRAVATO as the first and only monotherapy for adults with major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.

Key Players in Mood Disorders Market:

The key players in the Mood Disorders market who are in different phases of developing different therapies are GlaxoSmithKline, AstraZeneca, AbbVie, BioXcel Therapeutics, Otsuka Pharmaceutical, Sumitomo Pharma, Sunovion Pharmaceuticals, Takeda, BioLite Inc, Gate Neurosciences, Praxis Precision Medicines, and Others.

Regional Analysis:

The major markets for Mood Disorders include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for Mood Disorders while also representing the biggest market for its treatment. Novel treatments for Mood Disorders have recently emerged, including advanced pharmacological agents, neuromodulation therapies, and hormonal modulators that provide more targeted and effective solutions. Innovations such as AMPA receptor modulators and glutamate-based therapies are addressing limitations of traditional treatments by modulating neural pathways linked to mood regulation, offering faster and more sustained relief from depressive symptoms.

Recent advancements in diagnostic tools have enabled earlier and more accurate identification of mood disorders and their contributing factors. AI-powered analytics and wearable mental health monitors provide real-time insights into patient conditions, facilitating timely intervention and personalized treatment strategies with minimal side effects. Other key factors contributing to the growth of the Mood Disorders market include the approval of novel therapeutic guidelines, increased investment in R&D, and growing collaborations between pharmaceutical companies, mental health technology providers, and research institutes. AI-driven diagnostic tools and telemedicine platforms are playing a vital role in expanding access to advanced care for remote and underserved regions. With these advancements, regions like North America and Europe continue to lead in innovation, propelling the global market toward sustained growth and improved mental health outcomes.

Recent Developments in Mood Disorders Market:

• In January 2025, Boehringer Ingelheim announced top-line results from the Phase III CONNEX clinical program evaluating iclepertin for cognitive impairment in adults with schizophrenia. The primary and key secondary endpoints were not met, with no statistically significant improvements in cognition or functioning observed after six months of treatment compared to placebo. However, iclepertin, a glycine transporter 1 (GlyT1) inhibitor, was generally well tolerated, maintaining a safety profile consistent with previous studies.
• In September 2024, the U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use in the treatment of schizophrenia in adults. This marks the first antipsychotic approved to target cholinergic receptors rather than dopamine receptors, which have traditionally been the standard treatment approach.

Key information covered in the report.

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Mood Disorders market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Mood Disorders market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current Mood Disorders marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800